Advertisement

OnabotulinumtoxinA for Refractory Headache

  • Abigail L. ChuaEmail author
  • Sait Ashina
  • Richard Lipton
Chapter
Part of the Headache book series (HEAD)

Abstract

Refractory headaches, also known as treatment-resistant headaches, are a poorly defined and heterogeneous group of headache disorders. Chronic migraine is the most common clinical subtype of refractory headache. OnabotulinumtoxinA is widely used for the prophylactic treatment of chronic migraine. However, its effect on other refractory headaches, including chronic cluster headache and medication overuse headache, has not been fully clarified. This chapter reviews the pharmacological properties, efficacy, and tolerability of onabotulinumtoxinA, with special focus on its potential role in the treatment of refractory chronic migraine.

Keywords

Botox OnabotulinumtoxinA PREEMPT Chronic migraine Refractory headache Intractable headache Cluster headache Medication overuse headache Prophylaxis Prevention 

References

  1. 1.
    Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50(9):1499–506.CrossRefGoogle Scholar
  2. 2.
    Schulman EA, Peterlin BL, Lake AE 3rd, Lipton RB, Hanlon A, Siegel S, Levin M, Goadsby PJ, Markley HG. Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache. 2009;49(4):509–18.CrossRefGoogle Scholar
  3. 3.
    Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.CrossRefGoogle Scholar
  4. 4.
    Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci. 2014;1329:67–80.CrossRefGoogle Scholar
  5. 5.
    Butera C, Colombo B, Bianchi F, Cursi M, Messina R, Amadio S, Guerriero R, Comi G, DelCarro U. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A? Neurol Sci. 2016;37(10):1701–6.CrossRefGoogle Scholar
  6. 6.
    May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–64.CrossRefGoogle Scholar
  7. 7.
    Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13(8):615–24.CrossRefGoogle Scholar
  8. 8.
    Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018;78(5):589–600.CrossRefGoogle Scholar
  9. 9.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.CrossRefGoogle Scholar
  10. 10.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.CrossRefGoogle Scholar
  11. 11.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.CrossRefGoogle Scholar
  12. 12.
    Oterino A, Ramón C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain. 2011;12(2):235–8.CrossRefGoogle Scholar
  13. 13.
    Gooriah R, Buture A, Ahmed F. Evidence-based treatments for cluster headache. Ther Clin Risk Manag. 2015;11:1687–96.CrossRefGoogle Scholar
  14. 14.
    Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007;8(4):236–41.CrossRefGoogle Scholar
  15. 15.
    Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hartford Healthcare Headache Center, University of Connecticut School of MedicineWest HartfordUSA
  2. 2.BIDMC Comprehensive Headache Center, Beth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA
  3. 3.Montefiore Headache Center, Albert Einstein College of MedicineBronxUSA

Personalised recommendations